Peptide vaccines get an OS update

Martin Zacharias; Sebastian Springer

doi:10.1038/s41589-024-01608-2

Peptide vaccines get an OS update

Martin Zacharias
, Sebastian Springer

Chair of Theoretical Biophysics - Biomolecular Dynamics

Jacobs University Bremen

Research output: Contribution to journal › Comment/debate

Abstract

Peptide vaccines use antigenic peptide fragments to induce an immune response but are problematic because of the short half-life of peptides. A study now reports thioamide substitution in the peptide backbone as a strategy to enhance resistance to proteolysis and promote binding to the MHC I complex for T cell activation.

Original language	English
Pages (from-to)	549-550
Number of pages	2
Journal	Nature Chemical Biology
Volume	20
Issue number	5
DOIs	https://doi.org/10.1038/s41589-024-01608-2
State	Published - May 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41589-024-01608-2

Cite this

@article{69f1f2e05f884d0584b6a55f9b9aa89e,

title = "Peptide vaccines get an OS update",

abstract = "Peptide vaccines use antigenic peptide fragments to induce an immune response but are problematic because of the short half-life of peptides. A study now reports thioamide substitution in the peptide backbone as a strategy to enhance resistance to proteolysis and promote binding to the MHC I complex for T cell activation.",

author = "Martin Zacharias and Sebastian Springer",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc. 2024.",

year = "2024",

month = may,

doi = "10.1038/s41589-024-01608-2",

language = "English",

volume = "20",

pages = "549--550",

journal = "Nature Chemical Biology",

issn = "1552-4450",

publisher = "Nature Research",

number = "5",

}

TY - JOUR

T1 - Peptide vaccines get an OS update

AU - Zacharias, Martin

AU - Springer, Sebastian

N1 - Publisher Copyright: © Springer Nature America, Inc. 2024.

PY - 2024/5

Y1 - 2024/5

N2 - Peptide vaccines use antigenic peptide fragments to induce an immune response but are problematic because of the short half-life of peptides. A study now reports thioamide substitution in the peptide backbone as a strategy to enhance resistance to proteolysis and promote binding to the MHC I complex for T cell activation.

AB - Peptide vaccines use antigenic peptide fragments to induce an immune response but are problematic because of the short half-life of peptides. A study now reports thioamide substitution in the peptide backbone as a strategy to enhance resistance to proteolysis and promote binding to the MHC I complex for T cell activation.

UR - https://www.scopus.com/pages/publications/85189623137

U2 - 10.1038/s41589-024-01608-2

DO - 10.1038/s41589-024-01608-2

M3 - Comment/debate

C2 - 38580838

AN - SCOPUS:85189623137

SN - 1552-4450

VL - 20

SP - 549

EP - 550

JO - Nature Chemical Biology

JF - Nature Chemical Biology

IS - 5

ER -

Peptide vaccines get an OS update

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this